Health
FDA approves new indication for drug to treat pediatric NDO patients – News-Medical.Net
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for…
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older. Myrbetriq is also indicated for overactive bladder in adult patients.
Today’s action is a positive step for the treatment of NDO in young patients. Mirabegron,…
-
Noosa News20 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News24 hours agoStar’s Brisbane casino has been in the headlines for months: What’s the latest?
-
Noosa News21 hours agoE-biker charged with riding dangerously, assaulting cop
-
Business23 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025